Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: APC-80200, Dendreon.

Alison Rice1, Derek Hart

  • 1Mater Medical Research Institute, South Brisbane, Queensland, Australia.

Current Opinion in Molecular Therapeutics
|November 19, 2002
PubMed
Summary

APC-80200 (Mylovenge) is a therapeutic vaccine for B-cell malignancies, showing promise in advanced multiple myeloma patients post-chemotherapy and stem cell rescue. It is also under investigation for treating amyloidosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Embodying AACAP's Presidential Initiative to Combat Digital Racism in Youth.

Journal of the American Academy of Child and Adolescent Psychiatry·2024
Same author

Global Update on Measles Molecular Epidemiology.

Vaccines·2024
Same author

Evaluation of the sensitivity of a measles diagnostic real-time RT-PCR assay incorporating recently observed priming mismatch variants, 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2024
Same author

Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.

Transplantation·2017
Same author

The T Cell in Myeloma.

Clinical lymphoma, myeloma & leukemia·2016
Same author

Nomenclature of CD molecules from the Tenth Human Leucocyte Differentiation Antigen Workshop.

Clinical & translational immunology·2016

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • B-cell malignancies represent a significant area of unmet medical need.
  • Advanced multiple myeloma and amyloidosis are debilitating conditions requiring novel therapeutic strategies.

Purpose of the Study:

  • To evaluate APC-80200 (Mylovenge) as a therapeutic vaccine for B-cell malignancies.
  • To assess the efficacy of APC-80200 in patients with advanced multiple myeloma, particularly after high-dose chemotherapy and stem cell rescue.
  • To explore the potential of APC-80200 in treating amyloidosis.

Main Methods:

  • Phase II clinical trials are underway to assess the safety and efficacy of APC-80200.
  • The study involves patients with advanced multiple myeloma and amyloidosis.
  • Evaluation includes patients who have undergone high-dose chemotherapy and stem cell rescue to reduce tumor burden.

Main Results:

  • APC-80200 is a therapeutic vaccine candidate for B-cell malignancies.
  • Preliminary findings suggest potential benefit in advanced multiple myeloma patients following intensive treatment regimens.
  • Ongoing trials will provide further data on its clinical utility.

Conclusions:

  • APC-80200 (Mylovenge) demonstrates potential as a novel therapeutic vaccine for B-cell malignancies.
  • Its application in advanced multiple myeloma, especially post-chemotherapy and stem cell rescue, warrants further investigation.
  • The vaccine is also being explored for amyloidosis treatment, expanding its therapeutic scope.

Related Experiment Videos